Action YD Bio - YDES

YD Bio Ltd (YDES) Action

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

2,2123

( -20,71% )

Prix Achat

2,20

Prix Vente

2,28

Volume échangé

349 497

0,00 Fourchette du Jour 0,00

2,12 Plage de 52 semaines 25,00

Cap du marché

155,569M

Clôture Veille

2,79

Ouverture

Dernière Transaction

2.24

Dernière heure de transaction

14:11:07

Volume financier

VWAP

Volume moyen (3 m)

US$ 22 372

Actions en circulation

70 319 824

Rendement du Dividende (LTM)

Ratio Cours sur Bénéfices

-1,88

Bénéfice par action (BPA)

-1,29

Chiffre d'affairess (LTM)

510,36k

Bénéfice net (LTM)

-1,41M

YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan. YD Bio Limited a biopharmaceutical company focuses on blood-based cancer detection and develops stem cell- and exosome-based therapeutics to transform the treatment of spectrum of diseases with unmet medical needs. The company is based in Taipei, Taiwan.

Secteur

Healthcare

Industrie

Biotechnology & Life Sciences

Site Web

www.ydesgroup.com

Siège social

Taipei, Taiwan

Fondé

YD Bio Ltd est coté dans le secteur Healthcare de la NASDAQ avec le ticker YDES. Le dernier cours de clôture d'YD Bio était de US$2,79. Au cours de la dernière année, les actions de YD Bio ont été négociées dans une fourchette de prix de US$ 2,12 à US$ 25,00.

YD Bio compte actuellement 70 319 824 actions en circulation. La capitalisation boursière d'YD Bio est de US$155,57 million. YD Bio a un ratio cours/bénéfice (ratio PE) de -1.88.

YD Bio Limited Reports Full Year 2025 Financial Results

TAIPEI, Taiwan, April 30, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing...

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

Taipei, Taiwan, March 31, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

Taipei, Taiwan, Feb. 25, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq:...

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

TAIWAN, Jan. 29, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio Ltd” or the “Company”) (Nasdaq: YDES), a...

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

Taipei, Taiwan, Jan. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

Taipei, Taiwan, Jan. 05, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

Taipei, Taiwan, Dec. 16, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

Taipei, Taiwan, Dec. 09, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

Taipei, Taiwan, Dec. 02, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

Taipei, Taiwan, Nov. 24, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	-0.6077	-21.5496453901	2.82	3.9003	2.12	119402	2.68703742	CS
4	-2.4177	-52.2181425486	4.63	4.6999	2.12	38073	2.92358058	CS
12	-5.7777	-72.3116395494	7.99	8	2.12	23158	4.13029454	CS
26	-9.8077	-81.5948419301	12.02	13.105	2.12	30193	8.33198598	CS
52	-9.7877	-81.5641666667	12	25	2.12	48628	12.53669056	CS
156	-8.2877	-78.9304761905	10.5	31	2.12	32561	12.49593591	CS
260	-8.2877	-78.9304761905	10.5	31	2.12	32561	12.49593591	CS

YDES - Frequently Asked Questions (FAQ)

What is the current YD Bio Ltd share price?

The current share price of YD Bio Ltd is US$ 2,2123

How many YD Bio Ltd shares are in issue?

YD Bio Ltd has 70 319 824 shares in issue

What is the market cap of YD Bio Ltd?

The market capitalisation of YD Bio Ltd is USD 155,57M

What is the 1 year trading range for YD Bio Ltd share price?

YD Bio Ltd has traded in the range of US$ 2,12 to US$ 25,00 during the past year

What is the PE ratio of YD Bio Ltd?

The price to earnings ratio of YD Bio Ltd is -1,88

What is the cash to sales ratio of YD Bio Ltd?

The cash to sales ratio of YD Bio Ltd is 333,44

What is the registered address of YD Bio Ltd?

The registered address for YD Bio Ltd is No. 3, Xingnan St., Taipei, 115001

What is the YD Bio Ltd website address?

The website address for YD Bio Ltd is www.ydesgroup.com

Which industry sector does YD Bio Ltd operate in?

YD Bio Ltd operates in the Biotechnology & Life Sciences sector

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

YD Bio Ltd (YDES)

YD Bio Ltd (YDES) Action

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de YD Bio Ltd

YDES Dernières nouvelles

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection

YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics

YD Bio Limited Reports Full Year 2025 Financial Results

YD Bio and EG BioMed Jointly Launch Nationwide Telehealth Platform to Accelerate Commercialization of Cancer Detection and Decentralized Clinical Services Across the United States

YD Bio Limited Announces Strategic Partnership with YC Biotech Co., Ltd. to Establish a Taiwan-U.S. Dual-Core Regulatory Platform

YD Bio Limited Enters into Binding Letter of Intent to Acquire Safe Save Medical Cell Sciences & Technology Co., Ltd., Bolstering Leadership in Advanced Immunocell Therapy

YD Bio Enters into MOU to Merge with EG BioMed, Advancing DNA Methylation–Driven AI Platforms for Cancer Diagnostics and Drug Development

YD Bio Limited Announces Major Milestones and Unveils Robust 2026 Clinical and Commercial Roadmap

YD Bio Limited Expands U.S. Presence with Newly Planned California Facilities and Operations Center

YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN

YDES - Frequently Asked Questions (FAQ)

YDES Transactions

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Pourquoi rejoindre ADVFN?

Tout ce dont les traders professionnels ont besoin.

Supprimer les publicités